Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Edinburgh
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Edinburgh, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca34 Merck Sharp & Dohme LLC13 Janssen Research & Development, LLC12 AbbVie10 Hoffmann-La Roche9
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Edinburgh

252 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford
2026-12-16
Not yet open
AbbVie
Phase 3
520
Plymouth, Edinburgh, London, Portsmouth, Airdrie, Nottingham
2026-11-30
Recruiting
Incyte Corporation
Phase 3
426
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
2026-09-08
Recruiting
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd
Phase 1
50
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton
2026-09
Not yet open
Eisai Limited
Observational
400
Edinburgh, London, Motherwell
2026-08-31
Recruiting
Eli Lilly and Company
Phase 3
1,000
Bodmin, Edinburgh, Exeter, Glasgow, Liverpool, Motherwell, Oxford, Penzance
2026-08-14
Recruiting
Boehringer Ingelheim
Phase 3
390
Cambridge, Edinburgh, Manchester
2026-07-10
Recruiting
LARKSPUR BIOSCIENCES, INC.
Phase 1/2
120
Edinburgh
2026-07-07
Recruiting
AstraZeneca
Phase 3
1,200
Aberdeen, Addlestone, Banbury, Bristol, Edinburgh, Hounslow, Penzance, Poole
2026-07-06
Recruiting
AstraZeneca
Phase 3
750
Edinburgh, London, Manchester
2026-06-26
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bristol, Cottingham, Edinburgh, Exeter, Liverpool, London
2026-06-11
Recruiting
AstraZeneca
Phase 3
420
Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
2026-05-05
Recruiting
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
NCT07346144Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Trogenix ltd
Phase 1/2
68
Edinburgh
2026-04-21
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugsVisugromab·Visugromab RDE
CatalYm GmbH
Phase 2/3
518
Brighton, Cambridge, Dundee, Edinburgh, Guildford, Manchester, Newcastle upon Tyne
2026-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Cambridge, Edinburgh, Glasgow, Leicester, Withington, Birmingham, Cardiff, Southampton
2026-04-09
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
Edinburgh, London
2026-03-31
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey
2026-03-26
Recruiting
GlaxoSmithKline
Phase 1
97
Cambridge, Edinburgh
2026-03-23
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab
CatalYm GmbH
Phase 2
104
Edinburgh, London
2026-03-19
Recruiting
Eli Lilly and Company
Phase 3
1,000
Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham
2026-02-09
Recruiting
Peptilogics
Phase 2/3
240
Cambridge, Edinburgh, Norwich, Leeds
2026-02-03
Recruiting
Exciva GmbH
Phase 2/3
300
Edinburgh, Aberdeen
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Birmingham, Edgbaston, Trumpington, Exeter, Oxford, Edinburgh, London
2026-02-02
Recruiting
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Edinburgh, Truro, London, Withington
2026-01-19
Recruiting
Autolus Limited
Phase 2
35
Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Cardiff, Edinburgh, London, Manchester, Sutton
2026-01-16
Recruiting
AstraZeneca
Phase 1/2
84
Edinburgh, London, Manchester, Newcastle
2026-01-09
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Edinburgh, London
2026-01-09
Recruiting
Contineum Therapeutics
Phase 2
324
Leicester, London, Southampton, Edinburgh, Perth, Birmingham
2026-01-08
Recruiting
Norgine
Phase 3
212
Edinburgh, Newcastle upon Tyne, Sheffield, London, Birmingham
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
Recruiting
Eli Lilly and Company
Phase 3
800
Edinburgh, Huddersfield, London, Manchester, Plymouth, Worcester
2025-12-22
Recruiting
Angitia Incorporated Limited
Phase 2
80
Cambridge, Edinburgh, London, Oxford
2025-12-12
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield
2025-12-10
Active, closed
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
NCT07827651Skin Ageing, Healthy Ageing, Effect of Oral Nutritional Supplementation on Skin, Hair, Sleep, Energy, Cognition and Sexual Wellbeing in Healthy Adults, Longevity
IDI Skincare Limited
Not applicable
64
Edinburgh
2025-12-08
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Cambridge, Cottingham, Edinburgh, Greater London, Guildford, London, Metropolitan Borough of Wirral, Northwood
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield
2025-12-03
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Cambridge, Cardiff, Edinburgh, Liverpool, London, Nottingham, Oxford
2025-11-25
Recruiting
Summit Therapeutics
Phase 3
600
Canterbury, London, Aberdeen, Edinburgh, Liverpool, Manchester
2025-11-18
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston
2025-11-12
Recruiting
AstraZeneca
Phase 2
435
Belfast, Birmingham, Brighton, Cambridge, Dundee, Edinburgh, Exeter, Liverpool
2025-11-06
Recruiting
BioNTech SE
Phase 3
558
Brighton, Bristol, Cottingham, Edinburgh, Leeds, London, Oxford, Rhyl
2025-10-30
Recruiting
Eli Lilly and Company
Phase 3
1,100
Blackpool, Chester, Eastbourne, Edinburgh, Glasgow, London, Manchester, Southampton
2025-10-15
Recruiting
Pfizer
Phase 2/3
982
Cambridge, London, Edinburgh, Liverpool
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Cambridge, Edinburgh, Greater Manchester, London, Rainhill, Sheffield, Stockport
2025-10-01
Recruiting
ImmunityBio, Inc.
Phase 3
507
Belfast, Truro, Bodelwyddan, Cardiff, London, Southampton, Edinburgh, Guildford
2025-10-01
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Derby, Doncaster, Edinburgh, London, Wolverhampton
2025-09-30
Active, closed
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Aberdeen, Bristol, High Wycombe, Peterborough, Truro, Edinburgh, Birmingham, Blackpool
2025-09-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford
2025-08-06
Recruiting
Autolus Limited
Phase 1
18
Cambridge, Edinburgh, London, Sheffield
2025-08-04
Active, closed
Boehringer Ingelheim
Phase 1
16
Edinburgh, London
2025-07-29
Recruiting
Bristol-Myers Squibb
Phase 3
586
Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
Edinburgh, Glasgow, London, Cardiff, Manchester
2025-07-20
Active, closed
A Study to Assess THN391 in Subjects With Alzheimer's Disease
NCT06814730Alzheimer Disease, Early Onset
DrugTHN391
Therini Bio, Inc.
Phase 1
19
Edinburgh, London
2025-07-17
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Cambridge, Edinburgh, Leicester, Newcastle upon Tyne
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Not yet open
Santersus AG
Not applicable
73
Birmingham, Edinburgh, Liverpool, London
2025-07-01
Active, closed
Mundipharma Research Limited
Phase 2
60
Cambridge, Derby, Dundee, Edinburgh, Leeds, London, Manchester
2025-06-30
Recruiting
GlaxoSmithKline
Phase 3
961
Manchester, Portsmouth, Uxbridge, Bedford, Corby, Dagenham, Edinburgh, Glasgow
2025-06-23
Active, closed
Calluna Pharma AS
Phase 2
150
Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton
2025-06-20
Recruiting
Bladder EpiCheck European Haematuria Study
NCT06818136Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Nucleix Ltd.
Observational
800
Dunfermline, Cambridge, Edinburgh, London, Surrey Quays
2025-06-20
Recruiting
BioNTech SE
Phase 3
480
Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London
2025-06-10
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Brighton, Cambridge, Canterbury, Colchester, Edinburgh, Liverpool, London, Plymouth
2025-06-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Recruiting
Mediar Therapeutics
Phase 2
164
Birmingham, Cambridge, Edinburgh, Oxford
2025-05-05
Recruiting
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Active, closed
BioMarin Pharmaceutical
Phase 1
6
Edinburgh, London, Southampton
2025-02-21
Recruiting
Physio-Assist
Not applicable
622
Belfast, Birmingham, Edinburgh, Manchester, Newcastle upon Tyne
2025-02-03
Recruiting
NovoCure GmbH
Phase 3
741
London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester
2025-02-03
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Edinburgh, London, North Shields, Wolverhampton
2025-01-10
Recruiting
Janssen Research & Development, LLC
Phase 3
750
Barnet, Basingstoke, Christchurch, Edinburgh, Glasgow, Hereford, Larbert, Staffordshire
2025-01-09
Recruiting
Takeda
Phase 3
396
London, Edinburgh, Glasgow
2025-01-02
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield
2024-12-17
Active, closed
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea
Phase 2
81
Headington, Edinburgh, London
2024-12-11
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Newcastle upon Tyne, Manchester, Birkenhead, Edinburgh, Glasgow, London
2024-12-04
Recruiting
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-27
Active, closed
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Recruiting
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry
2024-11-15
Recruiting
Genentech, Inc.
Phase 1
410
Edinburgh, London, Manchester, Sutton
2024-11-14
Active, closed
Eli Lilly and Company
Phase 3
1,400
Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth
2024-10-24
Active, closed
Pfizer
Phase 3
600
Blackburn, Westcliff-on-Sea, Edinburgh, Glasgow, London, Metropolitan Borough of Wirral, Swansea
2024-10-21
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Recruiting
AstraZeneca
Observational
24,000
Edinburgh, London
2024-09-30
Recruiting
GlaxoSmithKline
Phase 1
845
Edinburgh, Glasgow, London, Manchester, Newcastle upon Tyne
2024-09-30
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Dundee, Glasgow, Birmingham, Belfast, Cambridge, Edinburgh, Liverpool, London
2024-09-11
Recruiting
AbbVie
Phase 2
590
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Recruiting
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
NCT06547840Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
Epsilogen Ltd
Phase 1
45
Bristol, Edinburgh, Leeds, London, Southampton
2024-09-03
Active, closed
Celgene
Phase 2
95
Southampton, Canterbury, Edinburgh, Nottingham
2024-08-30
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
DrugsEribulin·Pumitamig·Gemcitabine·Paclitaxel
BioNTech SE
Phase 2
83
Cottingham, Edinburgh, Leeds, London
2024-08-26
Recruiting
AbbVie
Phase 3
110
Cambridge, Sheffield, London, Norwich, Edinburgh
2024-08-08
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Bath, Birmingham, Bristol, Edinburgh, Guildford, London, Oxford, Plymouth
2024-07-22
Recruiting
CellProthera
Observational
48
Dundee, Edgbaston, Edinburgh, London
2024-07-20
Recruiting
Jazz Pharmaceuticals
Phase 3
286
London, Manchester, Surrey, Edinburgh
2024-07-19
Active, closed
Celldex Therapeutics
Phase 3
976
Bristol, Cambridge, Edinburgh, Glasgow, High Wycombe, Leeds, London, North Finchley
2024-07-19
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Edinburgh, London, Manchester, Oxford
2024-07-09
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Truro, Torquay, Bournemouth, Ashford, Blackpool, Harefield, Edinburgh, Glasgow
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Bristol, Hills Road, Truro, London, Edinburgh, Leeds
2024-06-24
Recruiting
AstraZeneca
Phase 3
240
Edinburgh, London, Wolverhampton
2024-06-20
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester
2024-06-03
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
134
Cambridge, Hull, Dundee, Edinburgh
2024-05-28
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Exeter, Bournemouth, Bristol, Edinburgh, London, Sheffield, Swansea
2024-05-20
Active, closed
AbbVie
Phase 3
421
Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester
2024-05-19
Active, closed
Pfizer
Observational
360
Glasgow, Nottingham, Oxford, Edinburgh, Crumpsall, Kent, London, Newport
2024-05-08
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London
2024-05-06
Active, closed
Hoffmann-La Roche
Phase 2
256
Chertsey, Edinburgh, London, Manchester, Southampton
2024-05-02
Recruiting
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
DrugVERVE-102
Verve Therapeutics, Inc.
Phase 1
85
Birmingham, Cambridge, Edinburgh, London, Manchester, Nottingham
2024-04-30
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
Cambridge, Glasgow, London, Edinburgh, Manchester
2024-04-10
Recruiting
Molecure S.A.
Phase 2
96
Birmingham, Cambridge, Edinburgh, London
2024-03-21
Recruiting
GlaxoSmithKline
Phase 3
864
Edinburgh, Gloucester, London, Nottingham, Sutton, Wolverhampton
2024-03-21
Recruiting
Verastem, Inc.
Phase 3
270
Glasgow, Cambridge, Edinburgh, Leicester, London, Manchester, Sutton
2024-03-18
Active, closed
Eli Lilly and Company
Phase 3
320
Bristol, Edinburgh, Glasgow, Nuneaton, Preston, Rochdale, Salford, Stevenage
2024-03-15
Recruiting
Eli Lilly and Company
Phase 3
90
Edinburgh, Headington, London, Manchester, Sheffield, Whitechapel
2024-03-13
Recruiting
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
NCT06271577Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases
AliveCor
Not applicable
1,000
Leeds, Edinburgh
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Reading, Portadown, Edinburgh, Leicester, Liverpool, London, Londonderry, Manchester
2024-03-07
Active, closed
Boehringer Ingelheim
Phase 3
428
Edinburgh, Leicester, London, Sutton
2024-02-09
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Southampton, Manchester, Edinburgh
2023-12-29
Recruiting
IONA Longitudinal Cohort Study
NCT05892952Alzheimer Disease, Dementia
Brain Health Scotland Life Sciences Ltd
Observational
10,000
Edinburgh
2023-12-21
Recruiting
Elios Vision, Inc.
Not applicable
194
East Grinstead, Edinburgh, Guildford, London, Manchester
2023-12-05
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 1/2
45
Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton
2023-11-29
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
London, Edinburgh
2023-11-20
Recruiting
United Therapeutics
Phase 3
698
Birmingham, Cambridge, Edinburgh, London, Manchester, Perth
2023-10-30
Active, closed
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
DrugNXP900
Nuvectis Pharma, Inc.
Phase 1
140
Edinburgh, London
2023-10-26
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Birmingham, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough, Exeter
2023-10-25
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Cambridge, Edinburgh, Birmingham, London, Manchester
2023-09-18
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Birmingham, Bristol, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough
2023-09-14
Active, closed
Hoffmann-La Roche
Phase 3
687
Edinburgh, London
2023-09-14
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Ilford, Swinton, London, Aberdeen, Chertsey, Edinburgh, Leeds, Motherwell
2023-08-28
Active, closed
Takeda
Phase 3
31
Cambridge, Edinburgh
2023-08-08
Recruiting
GlaxoSmithKline
Phase 3
892
Birmingham, Chelmsford, Cheltenham, Edinburgh, Hull, Leeds West Yorkshire, London, Manchester
2023-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Aberdeen, Windsor, Derby, Bournemouth, Portsmouth, Stoke-on-Trent, Edinburgh, London
2023-06-22
Active, closed
Exact Sciences Corporation
Observational
416
Headington, Edinburgh, Birmingham, Worcester, Ipswich, Kidderminster, Redditch, Torquay
2023-06-20
Active, closed
Neurogene Inc.
Phase 3
33
Edinburgh, Manchester
2023-06-13
Recruiting
H. Lundbeck A/S
Phase 3
315
Edinburgh, Great Yarmouth, Glasgow, London
2023-06-08
Recruiting
Hoffmann-La Roche
Phase 3
420
Basingstoke, Blackpool, Dumfries, Edinburgh, Harlow, Livingston, London, Maidstone
2023-06-07
Recruiting
Nova Eye, Inc.
Not applicable
86
Edinburgh, Liverpool, Manchester
2023-05-09
Recruiting
Regeneron Pharmaceuticals
Phase 1
107
Truro, Southampton, Edinburgh, Manchester
2023-04-20
Active, closed
Sanofi
Phase 2
999
London, Edinburgh, Sheffield
2023-04-03
Recruiting
AstraZeneca
Phase 3
4,300
Brighton, Burton-on-Trent, Cambridge, Derby, Edinburgh, Guildford, Ipswich, Keighley
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Edinburgh, London, Plymouth, Scunthorpe, Sheffield, Stevenage, Truro
2023-03-23
Recruiting
Takeda
Phase 3
160
Cambridge, Edinburgh, London, Nottingham, Plymouth
2023-03-06
Active, closed
Genmab
Phase 3
900
Birmingham, London, Norwich, Edinburgh
2023-02-08
By invitation
iSTAR Medical
Not applicable
30
Colchester, Edinburgh
2023-01-18
Recruiting
AstraZeneca
Phase 2
163
Edinburgh, Leeds, London, Oxford
2023-01-16
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton
2023-01-16
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Oxford, Edinburgh
2023-01-05
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Cottingham, Bellshill, Birmingham, Cardiff, Chesterfield, Chorley, Edinburgh, Hexham
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
2022-11-11
Recruiting
Pfizer
Phase 3
1,060
Leicester, London, Edinburgh, Oxford, Stoke-on-Trent, Birmingham, Cardiff, Glasgow
2022-11-10
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Birmingham, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Leeds, Liverpool
2022-11-08
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
Aberdeen, Edinburgh, London, Oxford
2022-11-07
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Active, closed
Eli Lilly and Company
Phase 3
8,000
Colchester, East Kilbride, Glasgow, Edinburgh, Liverpool, London, Manchester, Northwood, Plymouth
2022-10-04
Active, closed
Redx Pharma Ltd
Phase 2
48
Belfast, Birmingham, Cambridge, Edinburgh, London, Londonderry, Oxford
2022-09-08
Active, closed
Exelixis
Phase 3
901
Bristol, Birmingham, Edinburgh, London, Romford, Sutton
2022-09-07
Active, closed
Gilead Sciences
Phase 3
443
Edinburgh, Glasgow, Leeds, London, Nottingham
2022-07-25
Active, closed
STAR-LIFE: a Post-market Registry on MINIject
NCT05269680Open Angle Glaucoma
iSTAR Medical
Observational
320
Colchester, Edinburgh, London, Maidstone
2022-07-20
Recruiting
Collection of Blood Samples for New Diagnostic Devices 2
NCT05568966Embolism and Thrombosis, Cardiovascular, Renal, Inflammation
LumiraDx UK Limited
Observational
20,000
Airdrie, Edinburgh, Glasgow, Paisley
2022-07-11
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Newcastle upon Tyne, Edinburgh
2022-07-08
Active, closed
Janssen Research & Development, LLC
Phase 2
36
Edinburgh, London, Salford
2022-07-05
Recruiting
Nuvalent Inc.
Phase 1/2
840
Sutton, Edinburgh, London, Manchester
2022-06-09
Active, closed
Hoffmann-La Roche
Phase 3
188
Edinburgh
2022-05-19
Active, closed
AstraZeneca
Phase 3
644
Bristol, Cardiff, Edinburgh, London, Northampton, Nottingham, Warwick
2022-05-16
Recruiting
Zimmer Biomet
Observational
500
Edinburgh, Leeds, London
2022-04-11
Recruiting
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
NCT05329532Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
Scancell Ltd
Phase 1/2
168
Brighton, Cardiff, Edinburgh, Guildford, London, Manchester, Nottingham, Preston
2022-04-07
Active, closed
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
Belfast, Bristol, Dundee, Edinburgh, London, Middlesbrough, Poole, Torquay
2022-02-07
Active, closed
Microvention-Terumo, Inc.
Observational
206
Edinburgh, Liverpool, London
2022-01-14
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Edinburgh, Glasgow, Guildford, London, Newcastle upon Tyne, Nottingham
2021-12-10
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Bristol, Edinburgh, Leeds, London, Peterborough, Sheffield
2021-12-02
Recruiting
H. Lundbeck A/S
Phase 3
600
London, Edinburgh, Great Yarmouth, Glasgow
2021-12-01
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Cardiff, Edinburgh, London, Manchester
2021-11-17
Active, closed
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Active, closed
Hoffmann-La Roche
Phase 2
176
Edinburgh, London
2021-10-07
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth
2021-09-13
Active, closed
Immunome, Inc.
Phase 2/3
198
Edinburgh, Cambridge, London, Manchester
2021-09-01
Active, closed
HUYABIO International, LLC.
Phase 3
450
Eastleigh, Edinburgh
2021-08-12
Recruiting
H. Lundbeck A/S
Phase 3
285
Exeter, Edinburgh, Great Yarmouth, Glasgow, London
2021-06-30
Active, closed
GlaxoSmithKline
Phase 3
40
Bath, Brighton, Cardiff, Coventry, Edinburgh, Leeds, London, Maidstone
2021-06-28
Active, closed
AstraZeneca
Phase 3
506
Edinburgh
2021-06-22
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Edinburgh, Greater Manchester
2021-05-24
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Stoke-on-Trent, Bournemouth, Brighton, Bristol, Edinburgh, Glasgow, Leicester, Manchester
2021-05-15
Active, closed
Pfizer
Phase 3
599
Exeter, Maidstone, Preston, Edinburgh, Glasgow, Sheffield, Birmingham, London
2021-05-12
Active, closed
Alfasigma S.p.A.
Observational
1,304
Aberdeen, Barnet, Coventry, Doncaster, Dundee, Edinburgh, Liverpool, London
2021-05-11
Active, closed
Hoffmann-La Roche
Phase 3
761
Cambridge, Edinburgh, London, Plymouth, Preston, Sheffield, Southampton, Sutton
2021-05-03
Active, closed
AstraZeneca
Phase 3
1,157
Edinburgh, Guildford, London, Manchester, Swansea, Taunton
2021-04-26
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Birmingham, Leicester, Edinburgh, Glasgow, Manchester, Nottingham
2021-04-24
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford
2021-04-09
Active, closed
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Medtronic Cardiovascular
Not applicable
1,103
Edinburgh, Leeds
2021-04-02
Recruiting
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
DrugZimislecel
Vertex Pharmaceuticals Incorporated
Phase 3
57
Headington, Edinburgh, London, Newcastle upon Tyne
2021-03-29
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Aberdeen, Truro, Plymouth, Cottingham, London, Norwich, Swansea, Edinburgh
2021-03-09
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Birmingham, Edinburgh, Glasgow, Leicester, Manchester
2021-02-23
Active, closed
Stryker Neurovascular
Observational
405
Birmingham, Edinburgh
2020-12-21
Active, closed
Verastem, Inc.
Phase 2
225
Edinburgh, Glasgow, London, Manchester, Sutton
2020-12-21
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
GlaxoSmithKline
Phase 2/3
758
Cardiff, Edinburgh, London, Manchester
2020-12-08
Active, closed
MeiraGTx Ocular UK Ltd
Phase 3
97
Edinburgh, Glasgow, Leeds, London
2020-12-04
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
2020-12-02
Active, closed
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823Paravalvular Aortic Regurgitation
Abbott Medical Devices
Not applicable
200
Edinburgh, Brighton, Cambridge
2020-12-01
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Edinburgh, London, Sutton
2020-10-13
Active, closed
AbbVie
Phase 3
527
Cambridge, Exeter, Edinburgh, London, Southampton, Stevenage, Glasgow, Nottingham
2020-09-30
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Edinburgh, London, Manchester, Nottingham, Sutton
2020-09-30
Active, closed
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
DrugsAtirmociclib·Midazolam
Pfizer
Phase 2
362
Edinburgh, London, Manchester
2020-09-23
Active, closed
AbbVie
Phase 3
330
London, Lincoln, Great Yarmouth, Birmingham, Edinburgh, Newcastle upon Tyne
2020-08-31
Active, closed
AstraZeneca
Phase 3
185
Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton
2020-08-04
Active, closed
AstraZeneca
Phase 3
866
Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood
2020-07-24
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
DrugTemozolomide
Sapience Therapeutics
Phase 1/2
125
Edinburgh, Glasgow, Leeds, London
2020-07-01
Active, closed
Epizyme, Inc.
Phase 3
599
Edinburgh, London, Bebington, Cornwell, Glasgow, Middlesex
2020-06-11
Active, closed
GlaxoSmithKline
Phase 3
325
Airdrie, Dundee, Edinburgh, London, Nottingham, Oxford, Plymouth, Stoke-on-Trent
2020-04-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester
2020-02-27
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Truro, Edinburgh, Birmingham, London, Manchester, Sutton
2019-10-02
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
London, Manchester, Southampton, Maidstone, Northwood, Edinburgh, Glasgow
2019-08-09
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Walsall, Canterbury, Middlesbrough, London, Stevenage, Edinburgh, Metropolitan Borough of Wirral, Truro
2019-07-24
Active, closed
AstraZeneca
Phase 3
923
Edinburgh, London, Sheffield, Surrey, York
2019-06-25
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Plymouth, Bristol, Cardiff, Edinburgh, Glasgow, London, Manchester
2019-06-04
Recruiting
HighLife SAS
Not applicable
120
Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford
2019-05-28
Active, closed
AstraZeneca
Phase 3
1,063
Edinburgh, London, Metropolitan Borough of Wirral, Nottingham, Sheffield
2018-11-16
Active, closed
Zynerba Pharmaceuticals, Inc.
Phase 2/3
476
Leicester, Edinburgh, Manchester
2018-11-09
Recruiting
Sapna Vyas
Observational
3,000
Edinburgh
2018-11-01
Active, closed
AbbVie
Phase 3
1,242
Cambridge, Exeter, Edinburgh, London, Southampton, Barnsley, Liverpool, Newcastle upon Tyne
2018-08-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston
2018-08-21
Active, closed
pharmaand GmbH
Phase 3
1,097
Canterbury, Cliftonville, Brighton, Bristol, Cambridge, Edinburgh, Lancaster, Leeds
2018-05-14
Active, closed
AbbVie
Phase 3
1,336
Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford
2018-04-09
Active, closed
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Inverness
2017-09-12
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Birmingham, Edinburgh, London, Romford, Stoke-on-Trent
2016-12
Active, closed
Eisai Inc.
Phase 3
1,069
Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester
2016-10-13
Active, closed
Tesaro, Inc.
Phase 3
733
Blackburn, Edinburgh, Exeter, Glasgow, London, Portsmouth, Sheffield, Truro
2016-07-11
Active, closed
UK Infinity, Post-Market Clinical Follow-up Study
NCT03063593Arthritis, Rheumatoid, Post-traumatic Osteoarthritis, Degenerative Arthritis
Stryker Trauma and Extremities
Observational
500
Torquay, Bournemouth, Bothwell, Oswestry, Sheffield, Nottingham, Bristol, Edinburgh
2016-04-29
Active, closed
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
NCT02710435Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
Shockwave Medical, Inc.
Observational
400
Bradford, Edinburgh, London
2016-03
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Ayr, Belfast, Birmingham, Edinburgh, Glasgow, London, Manchester, Metropolitan Borough of Wirral
2014-11-26
Active, closed
AstraZeneca
Phase 3
1,837
Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cardiff, Dudley, Edinburgh
2014-04-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Birmingham, Cambridge, Coventry, Edinburgh, London, Sutton
2013-08-26
Active, closed
Novartis Pharmaceuticals
Phase 3
240
West Midlands, Edinburgh, London
2013-07-26
Active, closed
Survivorship of Attune Primary Total Knee Prosthesis
NCT01754363Noninflammatory Degenerative Joint Disease
DePuy International
Not applicable
1,542
Dunfermline, Gobowen, Edinburgh, Harlow, York
2013-02-01
Active, closed
AstraZeneca
Phase 2
162
Birmingham, Coventry, Edinburgh
2010-02-04
Active, closed
AstraZeneca
Phase 1
197
Edinburgh, London, Manchester, Newcastle upon Tyne, Northwood, Oxford, Sutton
2008-10-27
Active, closed
Genentech, Inc.
Phase 2
378
Dundee, Edinburgh, Grimsby, Lancaster, London, Manchester, Middlesex, Nottingham
2008-10-16
Rows per page Showing 1–252 of 252
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-uk/city/edinburgh

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 10 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 252 of those studies with a site in Edinburgh.

How many clinical trials are recruiting in Edinburgh?

133 of the 252 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:15 UTC sync. A further 4 have not yet opened recruitment, 114 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Edinburgh), 252 studies
PhaseStudiesRecruitingShare
Phase 31336152.8%
Phase 2452417.9%
Observational1997.5%
Phase 1/217166.7%
Phase 115106%
Not applicable1475.6%
Phase 2/3963.6%

Most active sponsors

Lead sponsors with the most studies (Edinburgh)
Lead sponsorStudiesRecruiting
AstraZeneca3415
Merck Sharp & Dohme LLC139
Janssen Research & Development, LLC127
AbbVie103
GlaxoSmithKline96
Hoffmann-La Roche92
Bristol-Myers Squibb84
Eli Lilly and Company85
Pfizer62
Boehringer Ingelheim52
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.